



SUVEN Life Sciences Ltd

Communication to investors
September 2016



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	FY 2016-17 Q2 to Q1	FY 2016-17 YoY (6 months)
Growth in revenue	-11.20%	13.42%
Growth in PAT	-18.54%	29.15%
Growth in EBIDTA	-8.96%	34.88%
Growth in Pre-R&D EBIDTA	-6.92%	22.27%
Increase in R&D Costs	-0.25%	-5.34%
R&D to sales	11.98%	11.28%





MAJOR PROFITABILITY RATIOS



	Q2 Sep 16	HY Sep 16
PAT to Income	21.62%	22.65%
EBIDTA to Income	35.68%	35.21%
Cash Flow to Income	25.44%	26.34%
Pre-R&D EBITDA to Income	47.66%	46.50%




Q2 to Q1 COMPARISON






REVENUE COMPARISON





PAT COMPARISON






EBIDTA COMPARISON





R & D – EXPENDITURE





PRE-R&D EBIDTA




24-Nov-16

2016-17 Q2 results



PRE-R&D CASHFLOW





FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2016-17 Q2	2016-17 Q1	Growth %	2015-16 Q2	Growth %	2016-17 HY	2015-16 HY	Growth %
Income	1,223.05	1,377.24	-11.20%	1,229.50	-0.52%	2,600.29	2,292.66	13.42%
Pre-R&D EBITDA	582.90	626.21	-6.92%	522.92	11.47%	1,209.11	988.86	22.27%
Pre-R&D EBITDA Margin	47.66%	45.47%		42.53%		46.50%	43.13%	
EBITDA	436.36	479.31	-8.96%	372.29	17.21%	915.67	678.87	34.88%
EBITDA Margin	35.68%	34.80%		30.28%		35.21%	29.61%	
EBIT	390.84	431.25	-9.37%	327.31	19.41%	822.09	604.85	35.92%
EBIT Margin	31.96%	31.31%		26.62%		31.62%	26.38%	
Financing costs	12.37	15.96		15.08		28.33	25.42	
Taxes	112.89	89.54		59.87		202.43	121.03	
Net Profit after tax	264.44	324.63	-18.54%	251.24	5.25%	589.07	456.13	29.15%
NP Margin	21.62%	23.57%		20.43%		22.65%	19.90%	
EPS (basic & diluted not annualised)	2.09	2.56		1.98		4.65	3.60	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	45.52	48.06		44.98		93.58	74.03	
R&D expenses	146.54	146.90	-0.25%	150.63	-2.72%	293.44	309.99	-5.34%

News Release



- During the period Suven secures 9 product patents covering India, Japan, Hong Kong, Canada, Israel, Europe, China and Mexico.
- Suven Life Sciences presented at Society for Neuroscience (SFN-2016) San Diego, USA
- Suven Life Sciences presented at Bio-Europe 2016 at Cologne, Germany
- Suven Life sciences presented at AAPS 2016 at Denver, USA
- Suven Life Sciences presented at Jefferies Healthcare Conference 2016 in London, UK